Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SAR445710

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Sanofi

Drug class:

PD-L1 inhibitor, IL-15R stimulant

Related drugs:

‹

PF-07209960 (0)

iC9.GD2.CAR.IL-15 T-cells (0)

atezolizumab (236)

durvalumab (199)

benmelstobart (12)

sugemalimab (7)

envafolimab (6)

IO102-IO103 (4)

socazolimab (2)

atezolizumab and hyaluronidase-tqjs (1)

adebrelimab (0)

CF33-hNIS-antiPDL1 (0)

PD-L1.t-haNK (0)

PF-07257876 (0)

Undisclosed anti-PD-L1 antibody (0)

cosibelimab-ipdl (0)

AGAR T cells (0)

GT-00A x IL15 (0)

GTB-3550 TRIKE (0)

PF-07209960 (0)

iC9.GD2.CAR.IL-15 T-cells (0)

›

PD-L1 negative	Colon Cancer	PD-L1 negative	Colon Cancer	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D
PD-L1 expression	Colon Cancer	PD-L1 expression	Colon Cancer	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D	SAR445710 Sensitive: D – Preclinical SAR445710 Sensitive : D